Rapid Sequence in a Child With an Undiagnosed Muscle Weakness: Does Succinylcholine Still Have a Role?
A single patient needing emergency rapid-sequence induction with a family history that makes one specific drug the very drug most guidelines warn hardest against. The disagreement is about whether the emergency itself outweighs a warning that exists precisely for emergencies like this one.
Julian W. is 6, and fourteen hours of worsening abdominal pain has turned into a surgical emergency his parents didn't see coming — acute appendicitis, a last meal three hours ago against the six hours a solid meal is meant to clear before induction — half the interval, in a child whose gastric emptying has been stalled by pain and an acute abdomen anyway, which is what makes this a full stomach rather than a borderline one — and a perforation risk that rises the longer surgery is delayed. The anesthetic question that actually matters tonight isn't about his appendix at all; it's about how to secure his airway safely and quickly against aspiration risk, which is what rapid sequence induction exists to do, and which neuromuscular blocker to use to get there — a choice that, for most children, wouldn't be a choice at all. Succinylcholine has been the traditional rapid-sequence agent of choice for exactly this scenario for decades, prized specifically for its rapid onset and short duration, properties that matter most when speed to a secured airway is the entire point.
What complicates tonight is a detail his mother mentioned only once directly asked about family medical history: a maternal cousin diagnosed with Duchenne muscular dystrophy at age 4. Julian himself has never been tested, has a normal gait and grossly normal strength on today's brief exam, and has no diagnosed muscle disease of his own — but succinylcholine's FDA-approved labeling carries a boxed warning written specifically around cases exactly like this: administration to children with undiagnosed myopathy, most often Duchenne or Becker muscular dystrophy, has caused sudden, severe hyperkalemia and cardiac arrest, driven by an abnormal proliferation of extrajunctional acetylcholine receptors in dystrophic muscle that succinylcholine's depolarizing mechanism triggers into a massive, uncontrolled potassium efflux rather than the modest, self-limited rise seen in normal muscle. The warning exists precisely because early signs are often absent — normal strength and gait, as Julian has today, do not reliably exclude early or mild dystrophinopathy in a young child, since clinical weakness in Duchenne itself is often not obvious until age 3-5 and can be subtler still in a boy whose relationship to an affected cousin, not a brother, carries a lower but real inherited-risk probability rather than a negligible one.
Emergency preoperative huddle, en route to the OR
Given the family history, I want to avoid succinylcholine tonight and use rocuronium at a full RSI dose instead, with sugammadex drawn up and immediately available. Undiagnosed dystrophinopathy causing catastrophic hyperkalemic cardiac arrest with succinylcholine is exactly the scenario the black-box warning was written to describe, and normal strength on a brief exam doesn't reliably rule it out in a 6-year-old.
If Julian had no family history at all, I wouldn't be raising any of this — succinylcholine remains an entirely reasonable RSI choice in a child with no reason to suspect myopathy. The history is what changes this specific decision.
I understand the concern, and I need to be direct about the other side of tonight's risk: this is a true full-stomach emergency with real aspiration danger, and rocuronium's onset, even at RSI dosing, has traditionally run slower than succinylcholine's — every additional second with an unprotected airway in a child this close to perforation is its own genuine danger.
I don't think 'theoretical, unconfirmed' should be dismissed either — but I also don't think it should categorically override a certain, immediate risk we're managing right now, in real time, with the clock already running.
I think the tradeoff both of you are debating is less severe than it used to be. At a true RSI dose of 1.2mg/kg, rocuronium's onset approaches succinylcholine's closely enough that the aspiration-risk gap is small, and sugammadex removes the old objection to nondepolarizing RSI entirely — if anything goes wrong, we can reverse rocuronium faster than succinylcholine would have worn off on its own.
So this isn't really succinylcholine's speed against Julian's safety anymore. It's a modern RSI technique that gets both: rocuronium 1.2mg/kg, sugammadex drawn up at the bedside before induction starts, standard RSI precautions otherwise unchanged.
Rapid sequence induction performed with rocuronium 1.2mg/kg in place of succinylcholine, sugammadex prepared and immediately available at the bedside; standard RSI precautions (preoxygenation, cricoid pressure per current practice, immediate airway team readiness) otherwise unchanged.
Not agreed, and the reason the plan carries an explicit branch point rather than a single expectation:
The rocuronium-sugammadex RSI approach is documented as having performed as intended, supporting its use for any future emergency in a child with a similarly unconfirmed but real family myopathy history.
The surgeon's aspiration-risk concern would carry retrospective weight, and the case would prompt closer review of whether RSI-dose rocuronium's onset genuinely matched the theoretical pharmacokinetic comparison in real practice.
Whether the modern rocuronium/sugammadex RSI approach should now be considered the default even for children with no family myopathy history at all, effectively retiring succinylcholine's traditional first-line role — that broader practice question wasn't raised or resolved tonight, only tonight's specific, history-driven decision.